{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:19:21Z","timestamp":1791389961138,"version":"4.3.3"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.clineuro.2019.105630","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T09:17:44Z","timestamp":1575278264000},"page":"105630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Temporal correlation between serum CH50 level and symptom severity of myasthenia gravis during eculizumab therapy"],"prefix":"10.1016","volume":"189","author":[{"given":"Mitsugu","family":"Yanagidaira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6158-9355","authenticated-orcid":false,"given":"Yoichiro","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Dec. (12)","key":"10.1016\/j.clineuro.2019.105630_bib0005","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"issue":"12","key":"10.1016\/j.clineuro.2019.105630_bib0010","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.4049\/jimmunol.179.12.8562","article-title":"Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis","volume":"179","author":"Zhou","year":"2014","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.clineuro.2019.105630_bib0015","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2014-03-560540","article-title":"Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab","volume":"125","author":"Regis","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clineuro.2019.105630_bib0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/1744666X.4.1.43","article-title":"Effect of complement and its regulation on myasthenia gravis pathogenesis","volume":"4","author":"Kusner","year":"2008","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"2","key":"10.1016\/j.clineuro.2019.105630_bib0025","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/01616412.2017.1407021","article-title":"Time-series analysis: variation of anti-acetylcholine receptor antibody titer in myasthenia gravis is related to incidence of Mycoplasma pneumoniae and influenza virus infections","volume":"40","author":"Iwasa","year":"2018","journal-title":"Neurol. Res."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846719304263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846719304263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:30:55Z","timestamp":1759588255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846719304263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":5,"alternative-id":["S0303846719304263"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2019.105630","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Temporal correlation between serum CH50 level and symptom severity of myasthenia gravis during eculizumab therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2019.105630","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105630"}}